Skip Navigation
Skip to contents

KDDW 2018

d-Day
D1991
  • Advancing Gastroenterology and Hepatology through Creative Integration
  • Abstract Submission and Registration are available via APDW 2018 website (www.apdw2018.org)

Program Details

Home    >    Scientific Program    >    Program Details
Symposium LV-01
Nov. 16 (Fri)
08:30-10:00		 Chronic hepatitis B: current medication 103 (1F)
Chairperson(s) Seung Kew Yoon (Seoul), George Lau (Hong Kong)
08:30-08:50 Can we stop the neucleot(s)ide analogue? George Lau
(Hong Kong)
08:50-09:10 Prevention of new HBV infection: nucleotide analogue in pregnant women and vaccination Henry LY Chan
(Hong Kong)
09:10-09:30 HBV and HCV coinfection Jidong Jia
(Beijing)
09:30-09:50 Bepatitis B prophylaxis and occult hepatitis B in immunocompromized patients: to whom and how long Seng Gee Lim
(Singapore)
09:50-10:00 Q&As
PG Course-LV (Korean)
Nov. 16 (Fri)
08:30-10:00		 Concerning points and management during treatment for liver disease E1+2 (3F)
Chairperson(s) So Young Kwon (Seoul), June Sung Lee (Goyang)
08:30-08:50 During antiviral therapy for HBV Hyun Phil Shin
(Seoul)
08:50-09:10 During antiviral therapy for HCV In Hee Kim
(Jeonju)
09:10-09:30 During imunosuppressive therapy for Autoimmune liver disease Eun Ju Cho
(Seoul)
09:30-09:50 During systemic therapy for HCC Sung-Bum Cho
(Gwangju)
09:50-10:00 Q&As
Symposium LV-02
Nov. 16 (Fri)
14:00-15:30		 Chronic hepatitis B: future treatment for the cure 103 (1F)
Chairperson(s) Seung Woon Paik (Seoul), Shiv Kumar Sarin (New Delhi)
14:00-14:20 Potential therapeutic target in hepatitis B virus life cycle Jia-Horng Kao
(Taipei)
14:20-14:40 Current strategies to maximize HBsAg loss in patients with CHB Pietro Lampertico
(Milan)
14:40-15:00 Immunologic modulation for hepatitis B treatment Antonio Bertoletti
(Singapore)
15:00-15:20 Emerging drugs?& new therapeutic perspectives?for HBV Henry LY Chan
(Hong Kong)
15:20-15:30 Q&As
Symposium LV-03
Nov. 16 (Fri)
16:00-17:30		 Chronic hepatitis C in DAA era 103 (1F)
Chairperson(s) Kwan Soo Byun (Seoul), Rakesh Aggarwal (Lucknow)
16:00-16:20 HCV screening in general population: is this cost-effective in DAA era? Rakesh Aggarwal
(Lucknow)
16:20-16:40 Is there difficult to treat population in HCV patients in DAA era? Naoya Sakamoto
(Sapporo)
16:40-17:00 Increased risk of HCC following DAA: fact or fiction?/Follow up strategy after SVR in chronic hepatitis C Yasuhiro Asahina
(Tokyo)
17:00-17:20 DAA first versus transplantation first in decompensated cirrhotic HCV patients Young-Suk Lim
(Seoul)
17:20-17:30 Q&As

Go to Top

Supported by
Member Societies
  • President : Dong Ki Lee
  • Business License No. 106-82-07189

Copyright© 2008 The Korean Society of Gastroenterlogy. All Rights Reserved.

Room 305, 31 Seolleung-ro 86 gil, Gangnam-gu, Seoul, 06193, Korea
Associated Societies
Secretariat